This content is part of a paid partnership with Breast Cancer Research Centre-WA.
Breast cancer prevention
Prevention of breast cancer is medically possible. In Australia, one in eight women will be diagnosed with breast cancer. In women with moderately (1.5 to 3 times average) and highly (3 times average or greater) increased lifetime risk of breast cancer, personalised risk reducing strategies are available. For example, five years of tamoxifen has been shown, in international studies involving thousands of women, to reduce the relative risk of breast cancer by at least 40% for those who have moderate to high lifetime risk of breast cancer.
This benefit continues for 20 years after completion of Tamoxifen. In some, this benefit is enough to reduce their lifetime breast cancer risk from moderate to average risk. Tamoxifen is currently available on the PBS, but the uptake is low.
As well as improving the awareness of drug efficacy and availability in Australia, a woman’s breast cancer risk needs to be accurately estimated. This is usually achieved through genetic counselling. We are especially lucky at BCRC-WA to work alongside Bhavya Vora, an associate genetic counsellor.
Hormone positive breast cancer
Approximately 70% of breast cancers are hormone positive. Traditionally, women with these breast cancers are recommended adjuvant endocrine treatment +/- chemotherapy to reduce risk of future recurrence and improve probabilities of cancer survival. In premenopausal young women who require adjuvant chemotherapy, adding gonadotrophin releasing hormone (GnRH) agonist, such as goserelin to adjuvant tamoxifen or the aromatase inhibitor Exemestane for five years had been shown to improve both recurrence free and overall survival and is now recommended standard practice in high-risk cases.
• Adding Abemaciclib
In women who have high risk early breast cancer, the monarchE study had shown that adding two years of abemaciclib, an oral drug that targets the CDK4/6 protein involved in cell cycling, to adjuvant endocrine treatment has led to a 30.4% reduction in the risk of developing new invasive breast cancer or cancer recurrence. The main side effects of this drug are diarrhoea and clinically insignificant neutropenia. This drug is not currently available on PBS.
• Chemotherapy decisions
To assist with decision making regarding adjuvant chemotherapy, the breast cancer tissue genomic testing Oncotype DX is available. This test is only useful for cancers up to 5cm with no nodal involvement or, if postmenopausal, with low nodal involvement (1-3 nodes). Unfortunately, Oncotype DX is not currently MBS funded and has an out-of-pocket cost of $5000, with a turn-around testing time of about three weeks.
Her2 positive breast cancer
About 15-20% of breast cancers are the Her2 amplified subtype. Adjuvant trastuzumab has been the poster child of targeted therapy in cancer treatments. Recently, antibody drug conjugates such as trastuzumab emtansine, which has been used to treat metastatic breast cancer, is now being used to treat early breast cancer. Women who needed neoadjuvant treatment for Her2 positive breast cancer will be offered adjuvant trastuzumab emtansine if there is residual invasive disease in the surgical specimen. This has been shown to improve survival rates when compared to using adjuvant trastuzumab alone and is available on PBS.
• Future treatments
Antibody drug conjugate trastuzumab-Deruxtecan and small molecule Her2 tyrosine kinase inhibitor Tucatinib is carrying great promise in studies, even in previously heavily pretreated patients with Her2 positive breast cancer and with central nervous system involvement. These drugs are currently unavailable.
Triple negative breast cancer
Chemotherapy treatment is the mainstay here. It is an area of need as it has a relatively poor prognosis. Since the CREATE-X study, six months of adjuvant capecitabine, an oral chemotherapy drug is now prescribed as standard practice if there is residual breast cancer after completion of neoadjuvant treatment.
Adding immunotherapy pembrolizumab to chemotherapy in the neoadjuvant setting had been shown to improve pathological complete response rates from 56% to 63%. In the metastatic setting, adding pembrolizumab to chemotherapy as first line treatment can improve progression free- and overall survival in patients with high PD-L1 expression (CPS>10). These drugs are not currently available on PBS.
• Metastatic cancer
Sacituzumab govitecan, an antibody drug conjugate targeting the trophoblast-cell-surface Ag2 (Trop-2) protein has outperformed standard treatment in the landmark ASCENT study even in heavily pretreated patients, regardless of Trop-2 expression. Significant overall survival benefit had been demonstrated and approval has been announced in the Federal Budget for 2022.
Questions? Contact the editor.
Disclaimer: Please note, this website is not a substitute for independent professional advice. Nothing contained in this website is intended to be used as medical advice and it is not intended to be used to diagnose, treat, cure or prevent any disease, nor should it be used for therapeutic purposes or as a substitute for your own health professional’s advice. Opinions expressed at this website do not necessarily reflect those of Medical Forum magazine. Medical Forum makes no warranties about any of the content of this website, nor any representations or undertakings about any content of any other website referred to, or accessible, through this website